Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis.
1. 系统已在2026-03-09 12:50:07对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
其他信息:
AA Hebert, FE Cook-Bolden, S Basu…
Journal of drugs in …, 2007
europepmc.org
Low to mid potency corticosteroids remain a cornerstone of therapy for atopic dermatitis (AD). Since AD is most prevalent in the younger pediatric population and is chronic in nature, safety is of particular concern especially for children under 2 years of age. A novel desonide (0.05%) formulation was developed in a nonirritating and moisturizing aqueous gel (hydrogel) that is free of alcohol and surfactants. The safety and efficacy of this new class VI low potency topical steroid was substantiated in 2 phase III clinical trials in mild to …
